Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2073 studies found for:    "Acute non lymphoblastic leukemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Acute non lymphoblastic leukemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
Condition: Acute Myeloblastic Leukaemia
Interventions: Drug: ARA-C;   Drug: Idarubicin;   Drug: Leucomax
2 Recruiting Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Azacitadine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Lenograstim;   Drug: Filgastrim
3 Unknown  Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
Condition: Acute Myeloid Leukemia
Intervention: Drug: Idarubicin
4 Recruiting Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Relapsed Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Intervention: Drug: cabozantinib
5 Unknown  Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: CHR-2797
6 Not yet recruiting Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Biological: NK Cells + Chemotherapy Starting
7 Completed Role of PTK-7 in Acute Myeloid Leukemias
Condition: Acute Myeloid Leukemia
Interventions: Other: Bone marrow aspiration;   Other: Blood sampling
8 Completed A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients
Condition: Acute Myeloid Leukemia
Intervention: Drug: OCV-501
9 Terminated
Has Results
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Low-dose cytarabine alone
10 Unknown  Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat
11 Not yet recruiting Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: guadecitabine;   Drug: Treatment Choice (TC)
12 Recruiting Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Interleukin-2
13 Terminated Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Troxatyl™ (Cytotoxic Chemotherapeutic)
14 Not yet recruiting A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Other: Standard Leukemia Care;   Other: Palliative Care
15 Recruiting A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia, in Relapse;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: GO-203-2c;   Drug: GO-203-2c + Decitabine
16 Completed Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)
Condition: Acute Myeloid Leukemia
Intervention: Drug: Cytarabine
17 Recruiting A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Condition: Acute Myeloid Leukemia
Intervention: Drug: AGS67E
18 Active, not recruiting Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: ASP2215
19 Withdrawn ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)
Condition: Acute Myeloid Leukemia
Interventions: Drug: Vesanoid (ATRA);   Drug: AZACITIDINE (VIDAZA);   Drug: CYTARABINE
20 Completed A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
Condition: Acute Myeloid Leukemia
Interventions: Drug: conventional chemotherapy (AraC + Daunorubicin),;   Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.